For research use only. Not for therapeutic Use.
AMA-37, an Arylmorpholine analog, is ATP-competitive DNA-PK inhibitor, with IC50 values of 0.27 μM (DNA-PK), 32 μM (p110α), 3.7 μM (p110β), and 22 μM (p110γ), respectively[1][2].
AMA-37 inhbits PI3K poorly[2].
AMA-37 (20 μM) reduces the ability of UCN-01, isogranulatimide, and debromohymenialdesine, but not caffeine, to overcome G2 arrest (ρ < 0.05)[3].
Inhibition of DNA-PK with AMA37 leads to radiosensitization[3].
| Catalog Number | I012833 |
| CAS Number | 404009-46-7 |
| Synonyms | (2-hydroxy-4-morpholin-4-ylphenyl)-phenylmethanone |
| Molecular Formula | C17H17NO3 |
| Purity | ≥95% |
| InChI | InChI=1S/C17H17NO3/c19-16-12-14(18-8-10-21-11-9-18)6-7-15(16)17(20)13-4-2-1-3-5-13/h1-7,12,19H,8-11H2 |
| InChIKey | FALILNHGILFDLC-UHFFFAOYSA-N |
| SMILES | C1COCCN1C2=CC(=C(C=C2)C(=O)C3=CC=CC=C3)O |
| Reference | [1]. Zachary A Knight, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006 May 19;125(4):733-47. [2]. Zachary A Knight, et al. Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg Med Chem. 2004 Sep 1;12(17):4749-59. [3]. Christopher M Sturgeon, et al. Effect of combined DNA repair inhibition and G2 checkpoint inhibition on cell cycle progression after DNA damage. Mol Cancer Ther. 2006 Apr;5(4):885-92. |
